ExelixisEXEL
Market Cap: $7.17B
About: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,310
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
101% more call options, than puts
Call options by funds: $62.5M | Put options by funds: $31M
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
0.44% less ownership
Funds ownership: 84.06% [Q1] → 83.62% (-0.44%) [Q2]
1% less funds holding
Funds holding: 411 [Q1] → 405 (-6) [Q2]
9% less capital invested
Capital invested by funds: $6.04B [Q1] → $5.47B (-$573M) [Q2]
13% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 48
19% less repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 170
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Truist Securities Asthika Goonewardene 38% 1-year accuracy 10 / 26 met price target | 31%upside $33 | Buy Reiterated | 8 Aug 2024 |
JMP Securities Silvan Tuerkcan 34% 1-year accuracy 14 / 41 met price target | 15%upside $29 | Market Outperform Maintained | 7 Aug 2024 |
RBC Capital Gregory Renza 45% 1-year accuracy 32 / 71 met price target | 7%upside $27 | Outperform Reiterated | 7 Aug 2024 |
Oppenheimer Jay Olson 39% 1-year accuracy 19 / 49 met price target | 15%upside $29 | Outperform Maintained | 30 Jul 2024 |
Financial journalist opinion
Based on 12 articles about EXEL published over the past 30 days